Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10426840-B2
Publication Date
2019-10-01
Expiration Date
Abstract
Disclosed is a palatable oral veterinary pharmaceutical composition consisting of an oil suspension of metronidazole and comprising metronidazole in an edible animal, vegetable or mineral oil and the use thereof for treating diarrhea in animals, in particular giardiasis or inflammatory diseases of the digestive tract.
Core Innovation
The invention relates to improving the acceptance by a domestic animal of an oral treatment for inflammatory diseases of the intestines, by administering an oily metronidazole suspension. The suspension comprises metronidazole particles and an edible animal, vegetable or mineral oil vehicle, with metronidazole provided as uncoated metronidazole particles having a narrowly defined equivalent diameter distribution.
A key aspect of the invention is the particle-size specification for acceptance improvement. The suspension is configured so that at least 90% of the uncoated metronidazole particles have an equivalent diameter strictly between 50 and 250 μm, and further embodiments tighten the distribution to 125–200 μm for at least 90% of the particles. The specification of equivalent diameter and the use of laser particle sizing are used to define the particle size distribution.
The disclosed formulation optionally further includes viscosifying agents, nonionic surface-active principles, flavoring agents, antioxidants, and dyes within described ranges and selection lists. The oily vehicle and uncoated particle presentation are presented as improving acceptance compared with aqueous suspension or human tablet forms, and the disclosed use context includes treatment of diarrhea, including giardiasis, and intestinal inflammatory diseases such as inflammatory bowel disease (IBD).
Claims Coverage
Two independent methods are identified. Both independently claim administering an oily metronidazole suspension with specified metronidazole/oil proportions and uncoated metronidazole particles having at least 90% strictly within a defined equivalent-diameter range.
Oily metronidazole suspension for intestinal inflammatory diseases acceptance
Administering to a domestic animal an effective amount of an oily metronidazole suspension comprising between 5% and 30% by weight/volume of metronidazole and between 70% and 95% by weight/volume of at least one edible animal, vegetable or mineral oil, wherein the metronidazole is provided as uncoated metronidazole particles with at least 90% having an equivalent diameter strictly between 50 and 250 μm.
Oily metronidazole suspension for diarrhea acceptance
Administering to a domestic animal an effective amount of an oily metronidazole suspension comprising between 5% and 30% by weight/volume of metronidazole and between 70% and 95% by weight/volume of at least one edible animal, vegetable or mineral oil, wherein the metronidazole is provided as uncoated metronidazole particles with at least 90% having an equivalent diameter strictly between 50 and 250 μm.
Across the two independent claims, the main inventive coverage is the administration of an oily metronidazole suspension with defined proportions of metronidazole and oil, combined with uncoated metronidazole particles having at least 90% strictly within a specified 50–250 μm equivalent-diameter range; dependent claims further narrow to 125–200 μm, specify optional excipients, and add dosing and scope refinements.
Stated Advantages
Improved acceptance of the oral metronidazole treatment by a domestic animal compared with other forms.
Documented Applications
Treating animal diarrhea, including giardiasis (Giardia intestinalis/duodenalis/lamblia).
Treating intestinal inflammatory diseases, including inflammatory bowel disease (IBD).
Interested in licensing this patent?